What is the tirzepatide titration schedule? 2.5 to 15 mg, step by step

The week-by-week titration schedule

Tirzepatide is a dual GIP and GLP-1 receptor agonist that is titrated slowly so the gut adapts and nausea stays manageable. Both FDA labels follow the same staircase: a 4-week 2.5 mg initiation step, then a move to 5 mg, then optional 2.5 mg increases every 4 weeks. The fastest a person can reach the 15 mg maximum is about 20 weeks if every step is taken at the minimum 4-week interval.

The dose levels themselves come straight from the pivotal trials. SURMOUNT-1 tested 5, 10, and 15 mg once weekly for obesity, and SURPASS-2 tested the same three doses against semaglutide 1 mg in type 2 diabetes. Those three strengths are exactly the approved maintenance doses today.

*The units column assumes a 10 mg/0.5 mL pen-equivalent concentration of 20 mg/mL, used here only to show the arithmetic. Single-dose pens deliver a fixed dose, so the unit figures matter mainly for compounded multi-dose vials where you draw the dose yourself. The week ranges are the minimum schedule; a prescriber may hold any dose longer.

How this is calculated

Two separate sums sit behind the schedule. The first is the titration calendar: pick a step, count at least 4 weeks, then consider the next 2.5 mg increase. The second is the syringe conversion, which only matters when you draw from a multi-dose vial rather than a fixed single-dose pen.

The conversion is one division and one multiplication. Volume in mL equals dose in mg divided by concentration in mg/mL. Units on a U-100 syringe equal that volume multiplied by 100, because 100 units is defined as 1 mL. Keep both numbers in the same mass unit (mg with mg/mL) before dividing.

Reading the dose staircase

The staircase shape is deliberate. Going up too fast is the main driver of nausea and dropout, which is why the labels build the 4-week hold into every step. If a step is poorly tolerated, prescribers often hold it longer or step back down rather than push forward.

Common titration mistakes

The first mistake is treating 2.5 mg as a long-term dose. It is an initiation step only; the label is explicit that it is not approved as a maintenance dose, so staying there indefinitely is off-label and usually under-dosed for the intended effect.

The second is increasing too early. Each 2.5 mg jump needs at least 4 weeks on the current dose. Jumping after 2 weeks doubles the chance of nausea and vomiting without speeding up the real result. The third is copying someone else's syringe units. Units only transfer between people if the vial concentration is identical, which is rarely true for compounded vials.

For investigational or compounded multi-dose vials, remember that no fixed-pen safety net exists: you are doing the dose-to-units maths yourself, so double-check it. This page is a maths reference, not medical advice, and the prescribed dose, schedule, and product must come from your prescriber.

So, what is the tirzepatide titration schedule?

The tirzepatide titration schedule steps from 2.5 mg once weekly up to 15 mg in 2.5 mg increments, holding each dose for a minimum of 4 weeks before any increase. The 2.5 mg starting dose is not a maintenance option; approved maintenance strengths are 5, 10, and 15 mg. At the fastest, reaching 15 mg takes 20 weeks. When drawing from a compounded multi-dose vial, use the GLP-1 titration calculator to convert each step into the exact syringe units for your vial concentration.

FAQs